Interferon alpha-2a biosimilar - Biogenomics
Alternative Names: Interferon alfa-2a biosimilar - BiogenomicsLatest Information Update: 04 Nov 2017
At a glance
- Originator Biogenomics
- Class Antineoplastics; Antivirals; Interferons
- Mechanism of Action Interferon alfa 2a stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- No development reported Chronic myeloid leukaemia; Hairy cell leukaemia; Hepatitis C; Kaposi's sarcoma
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for clinical-Phase-Unknown development in Chronic-myeloid-leukaemia in India (Parenteral, Injection)
- 04 Nov 2017 No recent reports of development identified for clinical-Phase-Unknown development in Hairy-cell-leukaemia in India (Parenteral, Injection)
- 04 Nov 2017 No recent reports of development identified for clinical-Phase-Unknown development in Hepatitis-C in India (Parenteral, Injection)